|
|
Other links at Articles > Allergy and Clinical Immunology |
| 2. |
Rituximab Reduces Brain Lesions, Clinical Relapses in RRMS
|
|
|
Results of a phase 2 trial show a single course of rituximab reduced both lesions on MRI and clinical relapses in relapsing-remitting multiple sclerosis. The results support the concept of B-cell involvement in the pathophysiology of the disease, researchers say. Medscape Medical News
|
|
|